FDA Approves First Cancer Drug Based on Broad Institute Science

The US FDA has approved sevabertinib, which was developed by Bayer Healthcare Pharmaceuticals in close collaboration with the Broad, and is the first FDA-approved medicine from the long-standing Broad-Bayer oncology research alliance.